Transplant Genomics

Executive Summary

Transplant Genomics, now a part of Eurofins, is a molecular diagnostics company dedicated to improving organ transplant outcomes through non-invasive blood-based gene expression profiling tests. Its core technology, Trāk™, enables early detection of graft injury and differentiation between rejection types (e.g., T-cell mediated vs. antibody-mediated) in kidney and liver transplant recipients. By replacing invasive biopsies with routine blood draws, the company addresses a critical unmet need in transplant surveillance, potentially reducing patient morbidity and healthcare costs. The platform leverages decades of research and has been commercialized through Eurofins' global laboratory network, offering diagnostic services under the brand Eurofins Transplant Genomics. Despite being private and integrated into a larger parent, Transplant Genomics retains a focused mission on transplant diagnostics, with its tests reimbursed by Medicare and selected private payers. The company's technology has been validated in multiple clinical studies, demonstrating high sensitivity and specificity for detecting subclinical rejection, which can lead to earlier intervention and improved graft survival. The growing prevalence of end-stage renal and liver diseases, coupled with the increasing number of transplant procedures, positions Transplant Genomics for steady adoption, though it faces competition from other non-invasive testing approaches such as donor-derived cell-free DNA assays.

Upcoming Catalysts (preview)

• Q2 2026Publication of pivotal clinical study data for Trāk™ kidney test expansion into pediatric population70% success
• Q4 2026Potential FDA clearance for expanded indication (e.g., liver transplant antibody-mediated rejection detection)50% success
• Q3 2026New partnership or licensing deal with a major transplant center network to increase test utilization60% success